Cingulate (CING) 10-K 1 Apr 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 22, 2024	Jun. 30, 2023
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-40874
Entity Registrant Name	Cingulate Inc.
Entity Central Index Key	0001862150
Entity Tax Identification Number	86-3825535
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1901 W. 47th
Entity Address, Address Line Two	Place
Entity Address, City or Town	Kansas City
Entity Address, State or Province	KS
Entity Address, Postal Zip Code	66205
City Area Code	(913)
Local Phone Number	942-2300
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 7.8
Entity Common Stock, Shares Outstanding		5,010,471
Documents Incorporated by Reference	None.
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	Kansas City, Missouri
Common Stock, par value $0.0001 per share
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CING
Security Exchange Name	NASDAQ
Warrants, exercisable for one share of common stock
Title of 12(b) Security	Warrants, exercisable for one share of common stock
Trading Symbol	CINGW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 52,416	$ 5,356,276
Miscellaneous receivables	14,622	234,432
Prepaid expenses and other current assets	511,556	2,278,944
Total current assets	578,594	7,869,652
Property and equipment, net	2,545,965	2,904,787
Operating lease right-of-use assets	366,877	630,618
Total assets	3,491,436	11,405,057
Current liabilities:
Accounts payable	5,199,105	762,357
Accrued expenses	1,651,519	894,635
Note payable	3,000,000	5,000,000
Finance lease liability, current	17,057	16,053
Operating lease liability, current	358,085	339,755
Total current liabilities	10,225,766	7,012,800
Long-term liabilities:
Finance lease liability, net of current	4,436	21,487
Operating lease liability, net of current	130,663	488,748
Total long-term liabilities	135,099	510,235
Total liabilities	10,360,865	7,523,035
Stockholders’ Equity
Common Stock, $0.0001 par value; 240,000,000 shares authorized and 1,167,520 and 602,640 shares issued and outstanding as of December 31, 2023 and 2022	118	61
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding as of December 31, 2023 and 2022
Additional Paid-in-Capital	86,073,896	73,290,457
Accumulated deficit	(92,943,443)	(69,408,496)
Total stockholders’ equity	(6,869,429)	3,882,022
Total liabilities and stockholders’ equity	$ 3,491,436	$ 11,405,057

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	240,000,000	240,000,000
Common stock, shares issued	1,167,520	602,640
Common stock, shares outstanding	1,167,520	602,640
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 15,493,304	$ 8,995,280
General and administrative	7,265,885	8,506,438
Operating loss	(22,759,189)	(17,501,718)
Interest and other expense, net	(775,758)	(174,514)
Loss before income taxes	(23,534,947)	(17,676,232)
Income tax benefit (expense)
Net loss and comprehensive loss	$ (23,534,947)	$ (17,676,232)
Net loss per share of common stock, basic	$ (26)	$ (29.35)
Net loss per share of common stock, diluted	$ (26)	$ (29.35)
Weighted average number of shares used in computing net loss per share of common stock, basic	905,225	602,340
Weighted average number of shares used in computing net loss per share of common stock, diluted	905,225	602,340

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2021	$ 61	$ 72,575,580	$ (51,732,264)	$ 165	$ 20,843,542
Balance, shares at Dec. 31, 2021	602,640
Available for sale investments				(165)	(165)
Stock-based compensation expense		800,796			800,796
IPO Costs		(85,919)			(85,919)
Net loss			(17,676,232)		(17,676,232)
Balance at Dec. 31, 2022	$ 61	73,290,457	(69,408,496)		3,882,022
Balance, shares at Dec. 31, 2022	602,640
Stock-based compensation expense		812,670			812,670
Net loss			(23,534,947)		(23,534,947)
Issuance of common stock in connection with At the Market Offering and Purchase Agreement, net of fees	$ 13	1,840,724			1,840,737
Issuance of common stock in connection with At the Market Offering and Purchase Agreement, net of fees, shares	126,312
Issuance of common stock in connection with private placement with WFIA	$ 9	999,991			1,000,000
Issuance of common stock in connection with private placement with WFIA, shares	91,158
Issuance of common stock in public offering, net of fees	$ 35	3,310,516			3,310,551
Issuance of common stock in public offering, net of fees, shares	346,260
Issuance of pre-funded warrants in connection with the conversion of related party note payable		3,949,765			3,949,765
Capital contribution in connection with conversion of related party note payable		1,862,735			1,862,735
Issuance of restricted common stock		7,038			7,038
Issuance of restricted common stock, shares	1,150
Balance at Dec. 31, 2023	$ 118	$ 86,073,896	$ (92,943,443)		$ (6,869,429)
Balance, shares at Dec. 31, 2023	1,167,520

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (23,534,947)	$ (17,676,232)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	582,918	394,011
Stock-based compensation	812,670	800,796
Changes in operating assets and liabilities:
Miscellaneous receivables	219,810	455,816
Prepaid expenses and other current assets	1,767,388	(580,591)
Operating lease right-of-use assets	263,741	227,982
Trade accounts payable and accrued expenses	5,193,632	791,005
Current portion of operating lease liability	18,330	44,160
Long-term portion of operating lease liability	(358,085)	(339,755)
Net cash used in operating activities	(15,034,543)	(15,882,808)
Investing activities:
Purchase of property and equipment	(224,096)	(153,420)
Proceeds from sale of short-term investments		933
Other		(165)
Net cash used in investing activities	(224,096)	(152,652)
Financing Activities:
Proceeds from the issuance of common stock and pre-funded common stock purchase warrants, net of fees	6,970,826
IPO issuance costs		(85,919)
Proceeds from note payable	3,000,000	5,000,000
Principal payments on finance lease obligations	(16,047)	(15,090)
Net cash provided by financing activities	9,954,779	4,898,991
Cash and cash equivalents:
Net decrease in cash and cash equivalents	(5,303,860)	(11,136,469)
Cash and cash equivalents at beginning of year	5,356,276	16,492,745
Cash and cash equivalents at end of year	52,416	5,356,276
Non-cash activities
Property and equipment accrued but not paid at end of year	186,960
Cash payments:
Interest paid	$ 19,421	$ 19,000

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (23,534,947)	$ (17,676,232)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of the Business and Liqu

Nature of the Business and Liquidity	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Nature of the Business and Liquidity	(1) Nature of the Business and Liquidity Organization Cingulate Inc. (Cingulate or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize a flexible core tableting technology with target product profile designed to deliver a rapid onset and last the entire active day with a controlled descent of plasma drug level and have favorable tolerability. In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Liquidity The Company has incurred losses and negative cash flows from operations since inception. As a pre-revenue entity, the Company is dependent on the ability to raise capital to support operations until such time as the product candidates under development are U.S. Food and Drug Administration (FDA) approved, manufactured, commercially available to the marketplace and produce revenues. The Company’s initial public offering, which was completed in December 2021, provided approximately $ 20.4 5.0 3.0 2.1 3.3 1 3.1 6.5

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies (a) Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. (b) Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. (c) Concentration of Credit Risk The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $ 250,000 (d) Cash and Cash Equivalents Bank demand deposit accounts and short-term liquid investments with an initial maturity of three months or less are considered cash and cash equivalents. Cash and cash equivalents as of December 31, 2023 and 2022 consisted of bank deposits and short-term money market funds. Cash and cash equivalents are carried at cost which is indicative of fair value. (e) Miscellaneous Receivables Miscellaneous receivables as of December 31, 2022, consisted of an insurance claim recoverable, which was subsequently collected in early 2023, as well as employee retention tax credits for payroll costs incurred in 2020 and research and development tax credits. The Company analogized to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance (f) Property and Equipment, net Property and equipment, net are stated at cost, less accumulated depreciation. Maintenance and repairs are charged to expense when incurred. Property and equipment are depreciated using the straight-line method over the estimated remaining useful lives or, for leasehold improvements or leased assets under a financing lease, the life of the lease if shorter. (g) Leases The Company is a lessee in two noncancellable operating leases, relating to office space at the Kansas City headquarters office and the New Jersey office and two finance leases, for certain furniture and equipment. The New Jersey office lease expired on December 31, 2023. The Company determines if an arrangement is or contains a lease at contract inception. The Company recognizes a ROU asset and a lease liability at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method. The Company determines the discount rate it uses to discount the unpaid lease payments to present value, which requires management judgement. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit rate was stated in the agreement for one of the Company’s leases; however, for the others, the implicit rate was not determinable as the Company did not have access to the lessor’s estimated residual value or the amount of the lessor’s deferred initial direct costs. Therefore, the Company uses its incremental borrowing rate as the discount rate for these leases. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company has not been able to borrow on a collateralized basis, it has determined a synthetic credit rating based on factors that a credit rating agency would typically analyze when establishing an entity’s credit rating. Due to the fact that the Company is a pre-revenue entity, the Company determined that its incremental borrowing rate should be based on the composite CCC and lower bond spreads at the lease measurement dates plus a risk-free rate based on specific lease maturities. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of cumulative lease incentives received. Lease expense is recognized on a straight-line basis over the lease term which includes the accretion of the lease liability and amortization of the ROU asset. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownerships of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. ROU assets for operating and finance leases are evaluated for impairment losses under the long-lived assets impairment guidance in ASC Subtopic 360-10, Property and Equipment-Overall Operating lease ROU assets are presented as operating lease right-of-use assets on the consolidated balance sheet. The current and long-term portions of operating lease liabilities are presented separately on the consolidated balance sheet. Finance lease ROU assets are included in property, plant, and equipment. The current and long-term portions of finance lease liabilities are presented separately on the consolidated balance sheet. (h) Impairment of Long-lived Assets The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No impairment was recognized during the years ended December 31, 2023 or 2022. (i) Research and Development Research and development costs are expensed as incurred and include all direct and indirect costs associated with the development of the Company’s product candidates. These expenses include payments to third parties for research, development and manufacturing services, personnel costs and depreciation on manufacturing equipment. At the end of the reporting period, the Company compares payments made to third party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. (j) Stock-Based Compensation The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 11. (k) Segments Operating segments are components of a Company for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one operating segment-drug development. (l) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. As of December 31, 2023, Cingulate Therapeutics LLC (CTx) is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items, therefore a full valuation allowance is recorded. The Company has not identified any uncertain tax positions. There have been no interest or penalties recognized in the consolidated financial statements related to uncertain tax positions. In addition, no tax positions exist for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company files income tax returns in the federal and various state jurisdictions. These federal income taxes are immaterial. The Company is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2020. (m) Common Stock Purchase Warrants The Company issued warrants in connection with its IPO in December 2021 and in connection with the common stock offering in September 2023. These equity instruments were valued at fair value when they were issued. See additional information in Note 11. (n) Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration to potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive instruments outstanding during the period using the simplified method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2023
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	(3) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following at December 31, 2023 and 2022: Schedule of Prepaid Expenses and Other Current Assets 2023 2022 Research and development $ 183,452 $ 1,377,391 Insurance 31,302 472,152 Active pharmaceutical ingredients 97,324 209,156 Deferred capital raise costs 178,780 100,339 Professional fees - 61,524 Dues and subscriptions - 37,684 Other 20,698 20,698 Total prepaid expenses and other current assets $ 511,556 $ 2,278,944

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	(4) Property and Equipment Property and equipment, net consists of the following at December 31, 2023 and 2022: Schedule of Property and Equipment Estimated Useful Life (in years) 2023 2022 Equipment 2 7 $ 4,321,816 $ 2,565,997 Furniture and fixtures 7 145,754 145,754 Computer equipment 5 41,898 41,898 Leasehold improvements 5 471,505 471,505 Construction-in-process- equipment - 207,976 1,739,699 Property and equipment, gross 5,188,949 4,964,853 Less: accumulated depreciation (2,642,984 ) (2,060,066 ) Property and equipment, net $ 2,545,965 $ 2,904,787 Depreciation expense was $ 582,918 394,011

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consisted of the following at December 31, 2023 and 2022: Schedule of Accrued Expenses 2023 2022 Employee compensation $ 593,022 $ 175,625 Interest 290,000 292,339 Professional fees 213,922 314,446 Research and development 155,220 - CIT- Equipment 155,800 - State franchise taxes 120,570 56,862 Insurance 56,088 - Other 66,897 55,363 Total accrued expenses $ 1,651,519 $ 894,635

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	(6) Contingencies The Company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business and otherwise. A substantial legal liability against us could have an adverse effect on our business, financial condition and results of operations. The Company records legal costs associated with loss contingencies as incurred and establishes reserves when those matters present material loss contingencies that management determines to be both probable and reasonably estimable in accordance with ASC 450, “Contingencies.”

Related Party Notes Payable

Related Party Notes Payable	12 Months Ended
	Dec. 31, 2023
Related Party Notes Payable
Related Party Notes Payable	(7) Related Party Notes Payable In August 2022, the Company received $ 5.0 15 3.0 8.0 On September 8, 2023, the Company and CTx entered into a Note Conversion Agreement (Note Conversion Agreement) with WFIA, pursuant to which WFIA agreed to convert the original principal amount of $ 5.0 5,812,500 341,912 17.00 11.55 The WFIA Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $ 0.002 The Company considered ASC 470-60, Troubled Debt Restructurings by Debtors 1,862,735 In February 2024, the remaining balance of the promissory note was converted to pre-funded warrants as described in Note 17. During the year ended December 31, 2023 and 2022, the Company recognized $ 790,000 292,339

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders’ Equity	(8) Stockholders’ Equity The Company has authorized 240,000,000 0.0001 10,000,000 0.0001 1,167,520 602,640 The holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any. Holders of the shares of common stock are entitled to dividends when, as and if declared by the Board of Directors. Reverse Stock Split On November 30, 2023, the Company completed a one-for-twenty reverse stock split 0.0001

Sale of Securities

Sale of Securities	12 Months Ended
	Dec. 31, 2023
Sale Of Securities
Sale of Securities	(9) Sale of Securities Private Placement On August 11, 2023, the Company entered into a Securities Purchase Agreement with WFIA and issued, in a private placement priced at the market under Nasdaq rules, 91,158 10.97 1.0 Public Offerings On September 11, 2023, the Company entered into a Securities Purchase Agreement with an institutional investor (September 2023 Offering) pursuant to which the Company issued 86,000 11.55 260,261 11.55 0.002 The September 2023 Offering closed on September 13, 2023. The Pre-Funded Warrants are exercisable at any time after the date of issuance and have no expiration date. The holder of Pre-Funded Warrants may not exercise the warrants if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. 3,999,480 688,929 In February 2024, the Company completed a public offering with net proceeds of $ 6.5 Conversion of Related Party Note On September 8, 2023, the Company issued WFIA Pre-Funded Warrants to purchase 341,912 The WFIA Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $ 0.002 In February 2024, the remaining balance of the promissory note was converted to pre-funded warrants as described in Note 17. Purchase Agreement with Lincoln Park In April 2023, the Company entered into a purchase agreement (LP Purchase Agreement) and a registration rights agreement (Registration Rights Agreement) with Lincoln Park Capital Fund, LLC (Lincoln Park). Pursuant to the terms of the LP Purchase Agreement, Lincoln Park has agreed to purchase from the Company up to $ 12 225,000 Pursuant to the terms of the LP Purchase Agreement, at the time the Company signed the LP Purchase Agreement and the Registration Rights Agreement, the Company issued 18,402 400,409 During 2023, the Company sold 25,500 450,427 At the Market Offering In January 2023, the Company entered into the ATM Agreement with H.C. Wainwright & Co., LLC (HCW) pursuant to which the Company may issue and sell, from time to time, shares of the Company’s common stock having an aggregate offering price of up to $ 4.97 3 82,410 1,696,407 In January 2024, the Company sold 283,800 3,115,303

Common Stock Purchase Warrants

Common Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2023
Common Stock Purchase Warrants
Common Stock Purchase Warrants	(10) Common Stock Purchase Warrants For each of the 208,333 120.00 31,250 .001 239,584 120.00 warrants are exercisable from December 10, 2021 through December 10, 2026. In addition to the common stock purchase warrants noted above, the Company issued 10,417 150.00 warrants are exercisable from June 7, 2023 through December 10, 2026 For each of the 346,261 346,261 173,131 11.55 five two Distinguishing Liabilities from Equity Derivatives and Hedging The Company valued the Pre-Funded Warrants to purchase 260,260 3,006,008 In connection with the September 2023 Offering, the Company issued placement agent warrants to purchase up to 17,313 14.44 The Series A, Series B and placement agent warrants issued in the September 2023 Offering were valued using a Black-Scholes model with a risk-free rate of 4.5 5.3 five two years 1.29 1.32 The following table summarizes the Company’s outstanding common stock purchase warrants as of December 31, 2023: Schedule of Warrants and Rights Outstanding Issuance Date Issuance Date Number of Exercise Fair Value Fair Value Warrants Price per Warrant Total December 2021 Initial Public Offering 239,584 $ 120.00 $ 95.40 $ 22,856,314 December 2021 Underwriter Warrants 10,418 $ 150.00 $ 92.79 966,686 September 2023 WFIA Pre-funded Warrants 341,912 $ 0.002 $ 11.55 3,949,767 September 2023 Public Offering Series A Warrants 346,261 $ 11.55 $ 10.82 3,746,544 September 2023 Public Offering Series B Warrants 173,131 $ 11.55 $ 8.42 1,457,763 September 2023 Placement Agent Warrants 17,316 $ 14.40 $ 10.63 184,069 Balance- December 31, 2023 1,388,882 $ 38,018,839 The Company has accounted for these warrants as equity-classified instruments under ASC Subtopic 815-40, Derivatives and Hedging Contracts in Entity’s Own Equity, Fair Value of the Warrants to Additional Paid in Capital Percent Fair of Total Amount Value Fair Value Allocated Common Stock $ 993,472 10.6 % $ 423,246 Pre-Funded Warrants 3,006,003 32.0 % 1,280,639 Series A, B and Placement Agent Warrants 5,388,376 57.4 % 2,295,594 Total $ 9,387,851 100.0 % $ 3,999,479

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(11) Stock-Based Compensation In September 2021, the Company’s board of directors and stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which provides for the grant of incentive stock options and non-qualified stock options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock units, restricted or unrestricted shares of common stock, performance shares, performance units, incentive bonus awards, other stock-based awards and other cash-based awards. No awards may be made under the 2021 Plan on or after September 24, 2031, but the 2021 Plan will continue thereafter while previously granted awards remain outstanding. The maximum number of shares of common stock available for issuance in connection with options and other awards granted under the 2021 Plan is 139,316 82,016 The number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur. The Company recorded stock-based compensation expense of $ 812,670 800,796 1,278,981 2,089,509 A summary of option activity under the Plan during the years ended December 31, 2023 and 2021 was as follows: Summary of Option Activity Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2022 25,043 Grants 18,017 $ 34.53 9.20 Exercised - Forfeitures or expirations - $ - Outstanding at December 31, 2022 43,060 Grants 31,817 $ 27.23 9.34 Exercised - Forfeitures or expirations (17,577 ) $ 51.55 Outstanding at December 31, 2023 57,300 $ 61.14 8.55 Vested and expected to vest at December 31, 2023 57,300 Exercisable at December 31, 2023 24,549 The Company’s stock options issued qualify for equity accounting treatment under ASC 718, Compensation- Stock Compensation Schedule of Fair Value Assumption 2023 2022 Risk-free interest rate 3.749 % 1.889 % Expected term (in years) 5.9 5.98 Expected volatility 1.20 1.126 Expected dividend yield 0 % 0 % Risk-Free Interest Rate Expected Term: Expected Volatility Expected Dividend Yield The grant-date fair value of options granted during the year ended December 31, 2023 ranged from $ 12.83 30.57 17.20 23.20 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock. Because there were no stock options with exercise prices lower than the fair value of the Company’s common stock, the aggregate intrinsic value is zero as of December 31, 2023 and 2022.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	(12) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. CTx is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. No deferred income tax benefit or expense was recorded as of December 31, 2023 or December 31, 2022, for federal or state income taxes. Income tax expense differed from the expected expense computed by applying U.S. Federal income tax rate for the respective years ended as follows: Schedule of Effective Income Tax Rate Reconciliation December 31, 2023 December 31, 2022 Federal income tax benefit at statutory rate $ (4,936,484 ) $ (3,712,008 ) State income tax benefit (1,299,941 ) (977,496 ) Permanent differences 18,239 11,935 Change in valuation allowance 7,050,437 4,733,324 Research and development tax crediit- prior period (775,982 ) - Other (56,269 ) (55,755 ) Total income tax expense $ - $ - Evaluating the need for, and amount of, a valuation allowance for deferred tax assets often requires significant judgment and extensive analysis of all available evidence on a jurisdiction-by-jurisdiction basis. Such judgments require the Company to interpret existing tax law and other published guidance as applied to its circumstances. As part of this assessment, the Company considers both positive and negative evidence about its profitability and tax situation. A valuation allowance is provided if, based on available evidence, it is more likely than not that all or some portion of a deferred tax asset will not be realized. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items. The Company recorded a valuation allowance of its net deferred tax assets totaling $ 12,631,033 5,580,595 The Company files income tax returns in the U.S. federal and various state jurisdictions. The Companies are not subject to U.S. federal and state income tax examinations by tax authorities for years before 2019. The Company follows the provisions of FASB ASC 740, Income Taxes Schedule of Deferred Tax Assets and Liabilities December 31, 2023 December 31, 2022 Deferred income tax assets: Current: Research and development costs $ 1,257,027 $ 343,087 Other 17,870 59,018 Non-current: - Net operating losses 6,515,232 3,381,215 Research and development costs 4,051,553 1,762,716 Unvested stock options 447,355 204,380 Research and development tax credits 756,123 - Patents 110,700 92,417 Right-of-use assets 38,706 63,563 Gross deferred income tax assets 13,194,566 5,906,396 Less: valuation allowance (12,631,033 ) (5,580,595 ) Net deferred income tax asset 563,533 325,801 Deferred income tax liabilities: Current: Accrual to cash - (11,228 ) Non-current Property and equipment (563,533 ) (314,573 ) Gross deferred income tax liabilities (563,533 ) (325,801 ) Net deferred tax asset (liability) $ - $ -

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases
Leases	(13) Leases In June, 2019, the Company executed a lease, which included expansion and renovation of previously leased space for the Kansas City office. The term of the lease is for a period of five years 30,453 33,145 201,600 The Company leases office space for its New Jersey based employees from a related party, as further described in Note 17. The base rent for this lease was $ 3,000 In April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $ 1,491 6.12 The components of lease cost for the years ended December 31, 2023 and 2022 were as follows: Summary of Components of Lease Cost 2023 2022 Operating lease cost $ 338,787 $ 338,787 Finance lease cost: Amortization of right-of-use assets 10,990 10,990 Interest on lease liabilities 1,853 2,804 Total finance lease cost 12,843 13,794 Total lease cost $ 351,630 $ 352,581 Amounts reported in the consolidated balance sheets as of December 31, 2023 and 2022 were as follows: Summary of Lease Reported in Consolidated Balance Sheets 2023 2022 Operating Leases: Operating lease right-of-use assets $ 366,877 $ 630,618 Operating lease liability, current 358,085 339,755 Operating lease liabilities, net of current 130,663 488,748 Total operating lease liabilities 488,748 828,503 Finance leases: Property and equipment 76,928 76,928 Accumulated amortization (44,988 ) (44,988 ) Property and equipment, net 31,940 31,940 Current installments of obligations under Finance lease liability, current 17,057 16,053 Finance lease liability, net of current 4,436 21,487 Total finance lease liabilities $ 21,493 $ 37,540 Other information relating to leases as of December 31, 2023 and 2022 was as follows: Summary of Other Information Relating to Leases 2023 2022 Supplemental cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 414,800 $ 406,400 Operating cash flow from finance leases 16,047 15,096 Financing cash flow from finance leases 1,853 2,804 Reductions to ROU assets resulting from reductions to lease obligations: Operating leases 263,741 227,981 Finance leases 10,990 10,990 Weighted average remaining lease term: Operating leases 17 25 Finance leases 12 27 Weighted average discount rate: Operating leases 11.76 % 11.62 % Finance leases 6.12 % 6.12 % Maturities of lease liabilities under noncancellable leases as of December 31, 2023 are as follows: Summary of Maturity of Lease Liabilities Operating Finance leases leases 2024 393,005 17,900 2025 132,580 4,475 Thereafter - - Total undiscounted lease payments 525,585 22,375 Less imputed interest (36,837 ) (882 ) Total lease liabilities $ 488,748 $ 21,493

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	(14) Net Loss Per Share Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of common shares and pre-funded warrants outstanding during the period. The pre-funded warrants are included in the calculation of the weighted-average number of shares outstanding because their exercise requires only nominal consideration for the delivery of shares. The following table sets forth the computation of the basic and diluted net loss per share for years ended December 31, 2023 and 2022: Schedule of Net Loss Per Share Basic and Diluted 2023 2022 Numerator: Net loss $ (23,534,947 ) $ (17,676,232 ) Denominator: Weighted average common shares outstanding 905,225 602,340 Net loss per share, basic and diluted $ (26.00 ) $ (29.35 ) Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: Schedule of Potentially Dilutive Securities 2023 2022 Stock options issued under the 2021 Equity Incentive Plan 57,300 43,060 Common stock purchase warrants outstanding 786,704 250,000 Total 844,004 293,060 Antidilutive securities 844,004 293,060

License Agreement

License Agreement	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreement	(15) License Agreement CTx has a licensing agreement with a company related to the patents and licensed know-how for use in the development of CTx-1301, CTx-1302, and CTx-2103. CTx will pay the following upon the occurrence of the following milestone events: ● $ 250,000 ● $ 250,000 ● $ 250,000 500,000 ● $ 250,000 As of December 31, 2022, the $ 250,000

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	(16) Related Party Transactions The former general counsel of the Company is a partner with a law firm providing office facilities space that was leased by the Company. Rental expense incurred by the Company to the law firm was $ 36,000 A member of the Company’s Board of Directors, Peter Werth, is the manager of WFIA, the entity which provided $ 8.0 5.0 3.0 5.0 790,000 292,339 290,000 292,339

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	(17) Subsequent Events Management evaluated events that occurred subsequent to December 31, 2023 through April 1, 2024, which is the date the financial statements were issued. In January 2024, the Company sold 283,800 3,115,303 On January 25, 2024, the Company and CTx entered into a note conversion agreement with WFIA, pursuant to which WFIA agreed to convert the remaining principal amount of the note payable of $ 3.0 million plus all accrued interest, or $ 3,287,500 , by issuing pre-funded warrants to purchase 694,096 shares of the Company’s common stock at a conversion price per pre-funded warrant of $ 4.785 . The closing price of the Company’s common stock on Nasdaq on January 24, 2024, was $ 4.35 per share. The pre-funded warrants have no expiration date and are exercisable immediately at an exercise price of $ 0.0001 per share, to the extent that after giving effect to such exercise, WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (Exchange Act), no more than 19.99% of the outstanding shares of common stock of the Company. On February 2, 2024, the Company completed a public offering (the February 2024 Offering) pursuant to which the Company issued 1,375,000 2.00 1,375,000 1.999 0.0001 The holder of Pre-Funded Warrants may not exercise the warrants if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each share of common stock and each pre-funded warrant were sold along with one Series A and 0.5 Series B warrants. 7,500,000 750,950 2,177,000 On March 18, 2024, the Company increased the maximum aggregate offering price of the shares of the Company’s common stock issuable under the ATM Agreement from $ 4,970,000 8,470,000 3,500,000 346,261 173,131 1.13

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	(b) Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
Concentration of Credit Risk	(c) Concentration of Credit Risk The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $ 250,000
Cash and Cash Equivalents	(d) Cash and Cash Equivalents Bank demand deposit accounts and short-term liquid investments with an initial maturity of three months or less are considered cash and cash equivalents. Cash and cash equivalents as of December 31, 2023 and 2022 consisted of bank deposits and short-term money market funds. Cash and cash equivalents are carried at cost which is indicative of fair value.
Miscellaneous Receivables	(e) Miscellaneous Receivables Miscellaneous receivables as of December 31, 2022, consisted of an insurance claim recoverable, which was subsequently collected in early 2023, as well as employee retention tax credits for payroll costs incurred in 2020 and research and development tax credits. The Company analogized to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance
Property and Equipment, net	(f) Property and Equipment, net Property and equipment, net are stated at cost, less accumulated depreciation. Maintenance and repairs are charged to expense when incurred. Property and equipment are depreciated using the straight-line method over the estimated remaining useful lives or, for leasehold improvements or leased assets under a financing lease, the life of the lease if shorter.
Leases	(g) Leases The Company is a lessee in two noncancellable operating leases, relating to office space at the Kansas City headquarters office and the New Jersey office and two finance leases, for certain furniture and equipment. The New Jersey office lease expired on December 31, 2023. The Company determines if an arrangement is or contains a lease at contract inception. The Company recognizes a ROU asset and a lease liability at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method. The Company determines the discount rate it uses to discount the unpaid lease payments to present value, which requires management judgement. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit rate was stated in the agreement for one of the Company’s leases; however, for the others, the implicit rate was not determinable as the Company did not have access to the lessor’s estimated residual value or the amount of the lessor’s deferred initial direct costs. Therefore, the Company uses its incremental borrowing rate as the discount rate for these leases. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company has not been able to borrow on a collateralized basis, it has determined a synthetic credit rating based on factors that a credit rating agency would typically analyze when establishing an entity’s credit rating. Due to the fact that the Company is a pre-revenue entity, the Company determined that its incremental borrowing rate should be based on the composite CCC and lower bond spreads at the lease measurement dates plus a risk-free rate based on specific lease maturities. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of cumulative lease incentives received. Lease expense is recognized on a straight-line basis over the lease term which includes the accretion of the lease liability and amortization of the ROU asset. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownerships of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. ROU assets for operating and finance leases are evaluated for impairment losses under the long-lived assets impairment guidance in ASC Subtopic 360-10, Property and Equipment-Overall Operating lease ROU assets are presented as operating lease right-of-use assets on the consolidated balance sheet. The current and long-term portions of operating lease liabilities are presented separately on the consolidated balance sheet. Finance lease ROU assets are included in property, plant, and equipment. The current and long-term portions of finance lease liabilities are presented separately on the consolidated balance sheet.
Impairment of Long-lived Assets	(h) Impairment of Long-lived Assets The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No impairment was recognized during the years ended December 31, 2023 or 2022.
Research and Development	(i) Research and Development Research and development costs are expensed as incurred and include all direct and indirect costs associated with the development of the Company’s product candidates. These expenses include payments to third parties for research, development and manufacturing services, personnel costs and depreciation on manufacturing equipment. At the end of the reporting period, the Company compares payments made to third party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.
Stock-Based Compensation	(j) Stock-Based Compensation The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 11.
Segments	(k) Segments Operating segments are components of a Company for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one operating segment-drug development.
Income Taxes	(l) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. As of December 31, 2023, Cingulate Therapeutics LLC (CTx) is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items, therefore a full valuation allowance is recorded. The Company has not identified any uncertain tax positions. There have been no interest or penalties recognized in the consolidated financial statements related to uncertain tax positions. In addition, no tax positions exist for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company files income tax returns in the federal and various state jurisdictions. These federal income taxes are immaterial. The Company is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2020.
Common Stock Purchase Warrants	(m) Common Stock Purchase Warrants The Company issued warrants in connection with its IPO in December 2021 and in connection with the common stock offering in September 2023. These equity instruments were valued at fair value when they were issued. See additional information in Note 11.
Net Loss per Share	(n) Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration to potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive instruments outstanding during the period using the simplified method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Prepaid Expenses And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following at December 31, 2023 and 2022: Schedule of Prepaid Expenses and Other Current Assets 2023 2022 Research and development $ 183,452 $ 1,377,391 Insurance 31,302 472,152 Active pharmaceutical ingredients 97,324 209,156 Deferred capital raise costs 178,780 100,339 Professional fees - 61,524 Dues and subscriptions - 37,684 Other 20,698 20,698 Total prepaid expenses and other current assets $ 511,556 $ 2,278,944

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following at December 31, 2023 and 2022: Schedule of Property and Equipment Estimated Useful Life (in years) 2023 2022 Equipment 2 7 $ 4,321,816 $ 2,565,997 Furniture and fixtures 7 145,754 145,754 Computer equipment 5 41,898 41,898 Leasehold improvements 5 471,505 471,505 Construction-in-process- equipment - 207,976 1,739,699 Property and equipment, gross 5,188,949 4,964,853 Less: accumulated depreciation (2,642,984 ) (2,060,066 ) Property and equipment, net $ 2,545,965 $ 2,904,787

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following at December 31, 2023 and 2022: Schedule of Accrued Expenses 2023 2022 Employee compensation $ 593,022 $ 175,625 Interest 290,000 292,339 Professional fees 213,922 314,446 Research and development 155,220 - CIT- Equipment 155,800 - State franchise taxes 120,570 56,862 Insurance 56,088 - Other 66,897 55,363 Total accrued expenses $ 1,651,519 $ 894,635

Common Stock Purchase Warrants

Common Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2023
Common Stock Purchase Warrants
Schedule of Warrants and Rights Outstanding	Schedule of Warrants and Rights Outstanding Issuance Date Issuance Date Number of Exercise Fair Value Fair Value Warrants Price per Warrant Total December 2021 Initial Public Offering 239,584 $ 120.00 $ 95.40 $ 22,856,314 December 2021 Underwriter Warrants 10,418 $ 150.00 $ 92.79 966,686 September 2023 WFIA Pre-funded Warrants 341,912 $ 0.002 $ 11.55 3,949,767 September 2023 Public Offering Series A Warrants 346,261 $ 11.55 $ 10.82 3,746,544 September 2023 Public Offering Series B Warrants 173,131 $ 11.55 $ 8.42 1,457,763 September 2023 Placement Agent Warrants 17,316 $ 14.40 $ 10.63 184,069 Balance- December 31, 2023 1,388,882 $ 38,018,839
Fair Value of the Warrants to Additional Paid in Capital	Fair Value of the Warrants to Additional Paid in Capital Percent Fair of Total Amount Value Fair Value Allocated Common Stock $ 993,472 10.6 % $ 423,246 Pre-Funded Warrants 3,006,003 32.0 % 1,280,639 Series A, B and Placement Agent Warrants 5,388,376 57.4 % 2,295,594 Total $ 9,387,851 100.0 % $ 3,999,479

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Option Activity	A summary of option activity under the Plan during the years ended December 31, 2023 and 2021 was as follows: Summary of Option Activity Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2022 25,043 Grants 18,017 $ 34.53 9.20 Exercised - Forfeitures or expirations - $ - Outstanding at December 31, 2022 43,060 Grants 31,817 $ 27.23 9.34 Exercised - Forfeitures or expirations (17,577 ) $ 51.55 Outstanding at December 31, 2023 57,300 $ 61.14 8.55 Vested and expected to vest at December 31, 2023 57,300 Exercisable at December 31, 2023 24,549
Schedule of Fair Value Assumption	Schedule of Fair Value Assumption 2023 2022 Risk-free interest rate 3.749 % 1.889 % Expected term (in years) 5.9 5.98 Expected volatility 1.20 1.126 Expected dividend yield 0 % 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense differed from the expected expense computed by applying U.S. Federal income tax rate for the respective years ended as follows: Schedule of Effective Income Tax Rate Reconciliation December 31, 2023 December 31, 2022 Federal income tax benefit at statutory rate $ (4,936,484 ) $ (3,712,008 ) State income tax benefit (1,299,941 ) (977,496 ) Permanent differences 18,239 11,935 Change in valuation allowance 7,050,437 4,733,324 Research and development tax crediit- prior period (775,982 ) - Other (56,269 ) (55,755 ) Total income tax expense $ - $ -
Schedule of Deferred Tax Assets and Liabilities	Schedule of Deferred Tax Assets and Liabilities December 31, 2023 December 31, 2022 Deferred income tax assets: Current: Research and development costs $ 1,257,027 $ 343,087 Other 17,870 59,018 Non-current: - Net operating losses 6,515,232 3,381,215 Research and development costs 4,051,553 1,762,716 Unvested stock options 447,355 204,380 Research and development tax credits 756,123 - Patents 110,700 92,417 Right-of-use assets 38,706 63,563 Gross deferred income tax assets 13,194,566 5,906,396 Less: valuation allowance (12,631,033 ) (5,580,595 ) Net deferred income tax asset 563,533 325,801 Deferred income tax liabilities: Current: Accrual to cash - (11,228 ) Non-current Property and equipment (563,533 ) (314,573 ) Gross deferred income tax liabilities (563,533 ) (325,801 ) Net deferred tax asset (liability) $ - $ -

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases
Summary of Components of Lease Cost	The components of lease cost for the years ended December 31, 2023 and 2022 were as follows: Summary of Components of Lease Cost 2023 2022 Operating lease cost $ 338,787 $ 338,787 Finance lease cost: Amortization of right-of-use assets 10,990 10,990 Interest on lease liabilities 1,853 2,804 Total finance lease cost 12,843 13,794 Total lease cost $ 351,630 $ 352,581
Summary of Lease Reported in Consolidated Balance Sheets	Amounts reported in the consolidated balance sheets as of December 31, 2023 and 2022 were as follows: Summary of Lease Reported in Consolidated Balance Sheets 2023 2022 Operating Leases: Operating lease right-of-use assets $ 366,877 $ 630,618 Operating lease liability, current 358,085 339,755 Operating lease liabilities, net of current 130,663 488,748 Total operating lease liabilities 488,748 828,503 Finance leases: Property and equipment 76,928 76,928 Accumulated amortization (44,988 ) (44,988 ) Property and equipment, net 31,940 31,940 Current installments of obligations under Finance lease liability, current 17,057 16,053 Finance lease liability, net of current 4,436 21,487 Total finance lease liabilities $ 21,493 $ 37,540
Summary of Other Information Relating to Leases	Other information relating to leases as of December 31, 2023 and 2022 was as follows: Summary of Other Information Relating to Leases 2023 2022 Supplemental cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 414,800 $ 406,400 Operating cash flow from finance leases 16,047 15,096 Financing cash flow from finance leases 1,853 2,804 Reductions to ROU assets resulting from reductions to lease obligations: Operating leases 263,741 227,981 Finance leases 10,990 10,990 Weighted average remaining lease term: Operating leases 17 25 Finance leases 12 27 Weighted average discount rate: Operating leases 11.76 % 11.62 % Finance leases 6.12 % 6.12 %
Summary of Maturity of Lease Liabilities	Maturities of lease liabilities under noncancellable leases as of December 31, 2023 are as follows: Summary of Maturity of Lease Liabilities Operating Finance leases leases 2024 393,005 17,900 2025 132,580 4,475 Thereafter - - Total undiscounted lease payments 525,585 22,375 Less imputed interest (36,837 ) (882 ) Total lease liabilities $ 488,748 $ 21,493

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Basic and Diluted	Schedule of Net Loss Per Share Basic and Diluted 2023 2022 Numerator: Net loss $ (23,534,947 ) $ (17,676,232 ) Denominator: Weighted average common shares outstanding 905,225 602,340 Net loss per share, basic and diluted $ (26.00 ) $ (29.35 )
Schedule of Potentially Dilutive Securities	Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: Schedule of Potentially Dilutive Securities 2023 2022 Stock options issued under the 2021 Equity Incentive Plan 57,300 43,060 Common stock purchase warrants outstanding 786,704 250,000 Total 844,004 293,060 Antidilutive securities 844,004 293,060

Nature of the Business and Li_2

Nature of the Business and Liquidity (Details Narrative) - USD ($)			1 Months Ended						12 Months Ended
	Feb. 29, 2024	Jan. 31, 2024	Feb. 29, 2024	Jan. 31, 2024	Sep. 30, 2023	May 31, 2023	Aug. 31, 2022	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of public offering								$ 20,400,000
Proceeds from issuance of debt						$ 3,000,000	$ 5,000,000
Notes payable									$ 2,100,000
Issuance of stock					$ 3,300,000				$ 6,970,826
Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of public offering	$ 6,500,000	$ 3,100,000	$ 7,500,000
Issuance of stock				$ 3,115,303
Subsequent Event [Member] | Series A and Series B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of public offering			$ 6,500,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of stock					$ 1,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative)	Dec. 31, 2023 USD ($)
Accounting Policies [Abstract]
Federal deposit insurance corporation limit	$ 250,000

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Research and development	$ 183,452	$ 1,377,391
Insurance	31,302	472,152
Active pharmaceutical ingredients	97,324	209,156
Deferred capital raise costs	178,780	100,339
Professional fees		61,524
Dues and subscriptions		37,684
Other	20,698	20,698
Total prepaid expenses and other current assets	$ 511,556	$ 2,278,944

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 5,188,949	$ 4,964,853
Less: accumulated depreciation	(2,642,984)	(2,060,066)
Property and equipment, net	2,545,965	2,904,787
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,321,816	2,565,997
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	2 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	7 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 145,754	145,754
Property and equipment, estimated useful life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 41,898	41,898
Property and equipment, estimated useful life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 471,505	471,505
Property and equipment, estimated useful life	5 years
Construction In Progress Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 207,976	$ 1,739,699

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 582,918	$ 394,011

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee compensation	$ 593,022	$ 175,625
Interest	290,000	292,339
Professional fees	213,922	314,446
Research and development	155,220
CIT- Equipment	155,800
State franchise taxes	120,570	56,862
Insurance	56,088
Other	66,897	55,363
Total accrued expenses	$ 1,651,519	$ 894,635

Related Party Notes Payable (De

Related Party Notes Payable (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Sep. 11, 2023	Sep. 08, 2023	May 31, 2023	Aug. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Aug. 09, 2023
Issuance of debt			$ 3,000,000	$ 5,000,000
Issuance of debt			3,000,000
Debt face amount			$ 8,000,000
Issuance date fair value total					$ 38,018,839
Number of warrants					1,388,882
Exercise price		$ 0.002
Debt instrument, description	The September 2023 Offering closed on September 13, 2023. The Pre-Funded Warrants are exercisable at any time after the date of issuance and have no expiration date. The holder of Pre-Funded Warrants may not exercise the warrants if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise.	The WFIA Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $0.002 per share, to the extent that after giving effect to such exercise, WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of common stock of the Company.
Capital contribution					$ 1,862,735
Interest expense					$ 790,000	$ 292,339
WFIA Pre Funded Warrants [Member]
Debt face amount		$ 5,000,000
Issuance date fair value total		$ 5,812,500
Number of warrants		341,912
Issuance date fair value per warrant		$ 17
Exercise price		11.55
Werth Family Investment Associates LLC [Member]
Issuance of debt				$ 5,000,000
Unsecured interest percentage							15%
Exercise price		$ 0.002
Debt instrument, description		The WFIA Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $0.002 per share, to the extent that after giving effect to such exercise, WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (Exchange Act), no more than 19.99% of the outstanding shares of common stock of the Company.

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - $ / shares	Nov. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Common stock, shares authorized		240,000,000	240,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Common stock, shares issued		1,167,520	602,640
Common stock, shares outstanding		1,167,520	602,640
Reverse stock splits, description	one-for-twenty reverse stock split

Sale of Securities (Details Nar

Sale of Securities (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Mar. 18, 2024

Feb. 29, 2024

Feb. 02, 2024

Jan. 31, 2024

Sep. 11, 2023

Sep. 08, 2023

Aug. 11, 2023

Feb. 29, 2024

Jan. 31, 2024

Sep. 30, 2023

Apr. 30, 2023

Jan. 31, 2023

Dec. 31, 2021

Dec. 31, 2023

Dec. 31, 2022

Jan. 24, 2024

Number of warrants

1,388,882

Exercise price

$ 0.002

Debt descripition

The September 2023 Offering closed on September 13, 2023. The Pre-Funded Warrants are exercisable at any time after the date of issuance and have no expiration date. The holder of Pre-Funded Warrants may not exercise the warrants if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise.

The WFIA Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $0.002 per share, to the extent that after giving effect to such exercise, WFIA and its affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of common stock of the Company.

Gross proceeds

$ 3,999,480

Placement agent fees

$ 688,929

Net proceeds from issuance of initial public offering

$ 20,400,000

Net proceeds

$ 3,300,000

$ 6,970,826

Number of shares issued

3,310,551

Purchase Agreement [Member] | Maximum [Member]

Net proceeds

$ 12,000,000

ATM Agreement [Member] | H.C. Wain Wright and Co LLC [Member]

Net proceeds

$ 1,696,407

Sale of stock, shares

82,410

Sale of stock commission percent

300%

ATM Agreement [Member] | Maximum [Member] | H.C. Wain Wright and Co LLC [Member]

Net proceeds

$ 4,970,000

Subsequent Event [Member]

Exercise price

$ 0.0001

Placement agent fees

$ 750,950

Net proceeds from issuance of initial public offering

$ 6,500,000

$ 3,100,000

7,500,000

Net proceeds

$ 3,115,303

Series A and Series B Warrants [Member]

Share price

$ 1.999

Number of warrants

1,375,000

86,000

Issuance date fair value per warrant

$ 11.55

Series A and Series B Warrants [Member] | Subsequent Event [Member]

Net proceeds from issuance of initial public offering

$ 6,500,000

Pre Funded Warrants [Member]

Number of warrants

260,261

260,260

Issuance date fair value per warrant

$ 11.55

Exercise price

$ 0.002

WFIA Pre Funded Warrants [Member]

Number of warrants

341,912

Issuance date fair value per warrant

$ 17

Exercise price

$ 11.55

Common Stock [Member]

Number of shares issued, shares

346,260

Share price

$ 1.13

Number of shares issued

$ 3,500,000

$ 35

Common Stock [Member] | Maximum [Member]

Number of shares issued

$ 8,470,000

Common Stock [Member] | Purchase Agreement [Member]

Number of shares issued, shares

18,402

Net proceeds

$ 450,427

Sale of stock

$ 225,000

Number of shares issued

$ 400,409

Sale of stock, shares

25,500

Common Stock [Member] | Subsequent Event [Member]

Number of shares issued, shares

1,375,000

283,800

Share price

$ 2

$ 4.35

Common Stock [Member] | Subsequent Event [Member] | ATM Agreement [Member]

Net proceeds

$ 3,115,303

Sale of stock, shares

283,800

Private Placement [Member]

Net proceeds

$ 1,000,000

Private Placement [Member] | Common Stock [Member]

Number of shares issued, shares

91,158

Share price

$ 10.97

Gross proceeds

$ 1

Schedule of Warrants and Rights

Schedule of Warrants and Rights Outstanding (Details) - USD ($)	Dec. 31, 2023	Sep. 08, 2023
Class of Warrant or Right [Line Items]
Number of warrants	1,388,882
Exercise price		$ 0.002
Issuance Date Fair Value Total	$ 38,018,839
December 2021 Initial Public Offering [Member]
Class of Warrant or Right [Line Items]
Number of warrants	239,584
Exercise price	$ 120
Issuance Date Fair Value Per Warrant	$ 95.40
Issuance Date Fair Value Total	$ 22,856,314
December 2021 Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants	10,418
Exercise price	$ 150
Issuance Date Fair Value Per Warrant	$ 92.79
Issuance Date Fair Value Total	$ 966,686
September 2023 WFIA Pre-funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants	341,912
Exercise price	$ 0.002
Issuance Date Fair Value Per Warrant	$ 11.55
Issuance Date Fair Value Total	$ 3,949,767
September 2023 Public Offering Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants	346,261
Exercise price	$ 11.55
Issuance Date Fair Value Per Warrant	$ 10.82
Issuance Date Fair Value Total	$ 3,746,544
September 2023 Public Offering Series B Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants	173,131
Exercise price	$ 11.55
Issuance Date Fair Value Per Warrant	$ 8.42
Issuance Date Fair Value Total	$ 1,457,763
September 2023 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants	17,316
Exercise price	$ 14.40
Issuance Date Fair Value Per Warrant	$ 10.63
Issuance Date Fair Value Total	$ 184,069

Fair Value of the Warrants to A

Fair Value of the Warrants to Additional Paid in Capital (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Fair value	$ 9,387,851
Percent of Total Fair Value	100%
Amount Allocated	$ 3,999,479
Common Stock [Member]
Fair value	$ 993,472
Percent of Total Fair Value	10.60%
Amount Allocated	$ 423,246
Pre Funded Warrants [Member]
Fair value	$ 3,006,003
Percent of Total Fair Value	32%
Amount Allocated	$ 1,280,639
Series A, B Placement Agent Warrants [Member]
Fair value	$ 5,388,376
Percent of Total Fair Value	57.40%
Amount Allocated	$ 2,295,594

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants (Details Narrative)		1 Months Ended	12 Months Ended
	Nov. 03, 2023	Sep. 30, 2023 $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022	Mar. 18, 2024 shares	Sep. 11, 2023 $ / shares shares	Sep. 08, 2023 $ / shares
Warrant exercise price | $ / shares							$ 0.002
Warrants exercisable, description			warrants are exercisable from December 10, 2021 through December 10, 2026.
Expected life			5 years 10 months 24 days	5 years 11 months 23 days
Number of warrants			1,388,882
Issuance Date Fair Value Total | $			$ 38,018,839
Series A Warrant [Member]
Number of warrants issued, shares		346,261
Warrant exercise price | $ / shares		$ 11.55
Expected life	5 years	5 years
Series B Warrant [Member]
Number of warrants issued, shares		173,131
Warrant exercise price | $ / shares		$ 11.55
Expected life	2 years	2 years
Number of warrants					173,131
Pre Funded Warrants [Member]
Warrant exercise price | $ / shares						$ 0.002
Number of warrants			260,260			260,261
Issuance Date Fair Value Total | $			$ 3,006,008
Placement Agent Warrants [Member]
Warrant exercise price | $ / shares		$ 14.44
Number of warrants		17,313
IPO [Member]
Number of warrants issued, shares			10,417
Warrant exercise price | $ / shares			$ 150
Warrants exercisable, description			warrants are exercisable from June 7, 2023 through December 10, 2026
Warrant [Member]
Number of warrants issued, shares		346,261	239,584
Warrant exercise price | $ / shares			$ 120
Warrant [Member] | Series A Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input		0.045
Warrant [Member] | Series A Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants measurement input		0.0129
Warrant [Member] | Series B Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input		0.053
Warrant [Member] | Series B Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants measurement input		0.0132
Warrant [Member] | IPO [Member]
Number of warrants issued, shares			208,333
Warrant exercise price | $ / shares			$ 120
Warrant [Member] | Over-Allotment Option [Member]
Number of warrants issued, shares			31,250
Warrant exercise price | $ / shares			$ 0.001

Summary of Option Activity (Det

Summary of Option Activity (Details) - 2021 [Equity Incentive Plan Plan Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Common stock options, outstanding at Beginning Balance	43,060	25,043
Number of Shares, Granted	31,817	18,017
Weighted Average Exercise Price, Granted	$ 27.23	$ 34.53
Weighted Average Remaining Contractual Life (Years) Outstanding	8 years 6 months 18 days	9 years 2 months 12 days
Number of Shares, Exercised
Number of Shares, Forfeitures or expirations	(17,577)
Weighted Average Remaining Contractual Term, Grants	9 years 4 months 2 days
Weighted Average Exercise Price, Forfeitures and expirations	$ 51.55
Number of Shares Common stock options, outstanding at ending balance	57,300	43,060
Weighted Average Exercise Price, Outstanding Ending Balance	$ 61.14
Shares, Vested and expected to vest	57,300
Shares, Exercisable	24,549

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	3.749%	1.889%
Expected term (in years)	5 years 10 months 24 days	5 years 11 months 23 days
Expected volatility	1.20%	1.126%
Expected dividend yield	0%	0%

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 812,670	$ 800,796
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant-date fair value of options	$ 12.83	$ 17.20
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant-date fair value of options	$ 30.57	$ 23.20
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, description	The number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur.
Stock-based compensation expense	$ 812,670	$ 800,796
Unrecognized compensation cost	$ 1,278,981		$ 2,089,509
2021 Equity Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock options	82,016
2021 Equity Incentive Plan [Member] | Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock options	139,316

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate	$ (4,936,484)	$ (3,712,008)
State income tax benefit	(1,299,941)	(977,496)
Permanent differences	18,239	11,935
Change in valuation allowance	7,050,437	4,733,324
Research and development tax crediit- prior period	(775,982)
Other	(56,269)	(55,755)
Total income tax expense

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Research and development costs	$ 1,257,027	$ 343,087
Other	17,870	59,018
Net operating losses	6,515,232	3,381,215
Research and development costs	4,051,553	1,762,716
Unvested stock options	447,355	204,380
Research and development tax credits	756,123
Patents	110,700	92,417
Right-of-use assets	38,706	63,563
Gross deferred income tax assets	13,194,566	5,906,396
Less: valuation allowance	(12,631,033)	(5,580,595)
Net deferred income tax asset	563,533	325,801
Accrual to cash		(11,228)
Property and equipment	(563,533)	(314,573)
Gross deferred income tax liabilities	(563,533)	(325,801)
Net deferred tax asset (liability)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Valuation allowance	$ 12,631,033	$ 5,580,595

Summary of Components of Lease

Summary of Components of Lease Cost (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating lease cost	$ 338,787	$ 338,787
Amortization of right-of-use assets	10,990	10,990
Interest on lease liabilities	1,853	2,804
Total finance lease cost	12,843	13,794
Total lease cost	$ 351,630	$ 352,581

Summary of Lease Reported in Co

Summary of Lease Reported in Consolidated Balance Sheets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating lease right-of-use assets	$ 366,877	$ 630,618
Operating lease liability, current	358,085	339,755
Operating lease liabilities, net of current	130,663	488,748
Total operating lease liabilities	488,748	828,503
Property and equipment	76,928	76,928
Accumulated amortization	(44,988)	(44,988)
Property and equipment, net	31,940	31,940
Finance lease liability, current	17,057	16,053
Finance lease liability, net of current	4,436	21,487
Total finance lease liabilities	$ 21,493	$ 37,540

Summary of Other Information Re

Summary of Other Information Relating to Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases
Operating cash flow from operating leases	$ 414,800	$ 406,400
Operating cash flow from finance leases	16,047	15,096
Financing cash flow from finance leases	1,853	2,804
Reductions to ROU assets resulting from reductions to lease obligations: Operating leases	263,741	227,981
Reductions to ROU assets resulting from reductions to lease obligations: Finance leases	$ 10,990	$ 10,990
Weighted average remaining lease term: Operating leases	17 months	25 months
Weighted average remaining lease term: Finance leases	12 months	27 months
Weighted average discount rate: operating leases	11.76%	11.62%
Weighted average discount rate: Finance leases	6.12%	6.12%

Summary of Maturity of Lease Li

Summary of Maturity of Lease Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Total lease liabilities	$ 488,748	$ 828,503
Total lease liabilities	21,493	$ 37,540
Operating Lease [Member]
Lessee, Lease, Description [Line Items]
2024	393,005
2025	132,580
Thereafter
Total undiscounted lease payments	525,585
Less imputed interest	(36,837)
Total lease liabilities	488,748
Finance Leases [Member]
Lessee, Lease, Description [Line Items]
2024	17,900
2025	4,475
Thereafter
Total undiscounted lease payments	22,375
Less imputed interest	(882)
Total lease liabilities	$ 21,493

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2020	Jun. 30, 2019	Dec. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Rent expense per month	$ 1,491
Lease description			In April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $1,491. The leased furniture is amortized on a straight-line basis over 7 years. The imputed interest rate relating to the lease obligation is 6.12% and the maturity date is March 2025.
Percentage of imputed interest rat, lease obligation			6.12%
Kansas City Office [Member]
Lessee, Lease, Description [Line Items]
Lease term		5 years
Lease incentive by lessor of tenant improvements		$ 201,600
Kansas City Office [Member] | Minimum [Member]
Lessee, Lease, Description [Line Items]
Rent expense per month		30,453
Kansas City Office [Member] | Maximum [Member]
Lessee, Lease, Description [Line Items]
Rent expense per month		$ 33,145
Office Facilities Space [Member]
Lessee, Lease, Description [Line Items]
Rent expense per month			$ 3,000	$ 3,000

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net loss	$ (23,534,947)	$ (17,676,232)
Weighted average number of shares used in computing net loss per share of common stock, basic	905,225	602,340
Weighted average number of shares used in computing net loss per share of common stock, diluted	905,225	602,340
Net loss per share of common stock, basic	$ (26)	$ (29.35)
Net loss per share of common stock, diluted	$ (26)	$ (29.35)

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	844,004	293,060
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	57,300	43,060
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	786,704	250,000

License Agreement (Details Narr

License Agreement (Details Narrative) - Licensing Agreements [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Phase 3 Clinical Trial [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	$ 250,000
New Drug Application [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	250,000
CTx-1301 and CTx-1302 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	250,000
CTx-2103 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	500,000
CTx-2103 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	$ 250,000
CTx-1301 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Accrued milestone payment		$ 250,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023	May 31, 2023
Related Party Transaction [Line Items]
Principal amount				$ 8,000,000
Interest expense	$ 790,000	$ 292,339
Accrued interest	290,000	292,339
Related Party [Member]
Related Party Transaction [Line Items]
Rental expense	36,000	36,000
Werth Family Investment Associates LLC [Member]
Related Party Transaction [Line Items]
Principal amount	$ 3,000,000	$ 5,000,000	$ 8,000,000
Werth Family Investment Associates LLC [Member] | Debt [Member]
Related Party Transaction [Line Items]
Principal amount			$ 5,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Mar. 18, 2024

Feb. 29, 2024

Feb. 02, 2024

Jan. 31, 2024

Jan. 25, 2024

Sep. 11, 2023

Feb. 29, 2024

Jan. 31, 2024

Sep. 30, 2023

Dec. 31, 2021

Dec. 31, 2023

Dec. 31, 2022

Apr. 01, 2024

Jan. 24, 2024

Sep. 08, 2023

May 31, 2023

Subsequent Event [Line Items]

Net proceeds

$ 3,300,000

$ 6,970,826

Debt Instrument, Face Amount

$ 8,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.002

Number of warrants

1,388,882

Pre funded warrants description

warrants are exercisable from December 10, 2021 through December 10, 2026.

Gross proceeds

$ 20,400,000

Placement agent fees

$ 688,929

Share issuance value

$ 3,310,551

Series A and Series B Warrants [Member]

Subsequent Event [Line Items]

Share price

$ 1.999

Number of warrants

1,375,000

86,000

Warrant [Member]

Subsequent Event [Line Items]

Number of warrants

346,261

Series B Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 11.55

Number of warrants

173,131

Common Stock [Member]

Subsequent Event [Line Items]

Issuance of shares

346,260

Share price

$ 1.13

Share issued price

$ 0.0001

Share issuance value

$ 3,500,000

$ 35

Common Stock [Member] | Minimum [Member]

Subsequent Event [Line Items]

Share issuance value

4,970,000

Common Stock [Member] | Maximum [Member]

Subsequent Event [Line Items]

Share issuance value

$ 8,470,000

Warrant [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 120

Subsequent Event [Member]

Subsequent Event [Line Items]

Net proceeds

$ 3,115,303

Debt Instrument, Face Amount

$ 3,000,000

Interest and Dividends Payable, Current

$ 3,287,500,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.0001

Pre funded warrants description

The holder of Pre-Funded Warrants may not exercise the warrants if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each share of common stock and each pre-funded warrant were sold along with one Series A and 0.5 Series B warrants.

Gross proceeds

$ 6,500,000

$ 3,100,000

$ 7,500,000

Placement agent fees

750,950

Subsequent Event [Member] | Series A and Series B Warrants [Member]

Subsequent Event [Line Items]

Gross proceeds

$ 6,500,000

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Issuance of shares

1,375,000

283,800

Share price

$ 2

$ 4.35

Subsequent Event [Member] | Warrant [Member]

Subsequent Event [Line Items]

Issuance of shares

694,096

Debt Instrument, Convertible, Conversion Price

$ 4.785

Number of warrants

2,177,000